AnaptysBio
ANAB
127 hedge funds and large institutions have $1.7B invested in AnaptysBio in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 25 reducing their positions, and 22 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 25
3.9% more ownership
Funds ownership: 107.95% → 111.85% (+3.9%)
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
2% less funds holding
Funds holding: 129 → 127 (-2)
20% less capital invested
Capital invested by funds: $2.13B → $1.7B (-$425M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less call options, than puts
Call options by funds: $5.51M | Put options by funds: $11.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$78.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$37M |
| 3 |
Millennium Management
New York
|
+$35M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$24.5M |
| 5 |
BlackRock
New York
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$17.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.8M |
| 3 |
DM
Deerfield Management
New York
|
-$14.6M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$8.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.77M |
ANAB Hedge Fund Activity: Q2 2019 in Review
127 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2019, worth a combined $1.7B — down 20% from $2.13B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ANAB positions and 22 closed out — a net gain of 1 holder — while 60 added to existing stakes and 25 trimmed.
The largest buyer was Invesco, adding an estimated $78.7M. The largest seller was Wells Fargo, cutting an estimated $17.8M.
- 127 institutional investors held AnaptysBio (ANAB) as of Q2 2019, down from 129 in Q1 2019.
- Funds reported $1.7B of AnaptysBio stock for Q2 2019, down 20% quarter-over-quarter.
- 23 funds opened new AnaptysBio positions in Q2 2019 and 22 closed out, a net change of +1 holder.
- The largest AnaptysBio buyer in Q2 2019 was Invesco, an estimated $78.7M added.
- The largest AnaptysBio seller in Q2 2019 was Wells Fargo, an estimated $17.8M sold.
Based on aggregated 13F filings for Q2 2019.